Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial

Chimeric antigen receptor (CAR)-T cell therapy showed preliminary activity in patients with refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL). However, many obstacles remain, including manufacturing difficulties and risk of infections. This phase I study (NCT04840875) evaluated...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular therapy 2024-09
Hauptverfasser:	Zhao, Liping, Li, Chuo, Zuo, Shiyu, Han, Yajing, Deng, Biping, Ling, Zhuojun, Zhang, Yanlei, Peng, Shuixiu, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Yu, Xinjian, Zheng, Qinlong, Xu, Xiuwen, Yuan, Ying, Tian, Zhenglong, Tang, Kaiting, Zhang, Yibing, Niu, Qing, Zhang, Jiecheng, Chang, Alex H., Luo, Yuechen, Feng, Xiaoming, Pan, Jing
Format:	Artikel
Sprache:	eng
Schlagworte:	CAR-T CD7 safety stem cell transplantation T cell acute lymphoblastic leukemia T cell pre-selection
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!